Gene-specific methylation status

All breast cancer cases

Methylated breast tumor

Unmethylated breast tumor

Genes

Recreational physical activitya

ER+PR+/
All others

OR

 (95% CI)

 

ER+PR+/
All others

OR

 (95% CI)

 

ER+PR+/
All others

OR

 (95% CI)

p for interaction

APC

Inactive

55/41

1.00

reference

25/21

1.00

reference

30/20

1.00

reference

0.164

Low RPA

69/61

0.84

(0.50, 1.44)

32/31

0.87

(0.40, 1.87)

37/30

0.82

(0.39, 1.73)

High RPA

73/39

1.40

(0.80, 2.45)

40/21

1.60

(0.73, 3.52)

33/18

1.22

(0.55, 2.74)

BRCA1

Inactive

63/45

1.00

reference

35/27

1.00

reference

28/18

1.00

reference

0.259

Low RPA

74/61

0.87

(0.52, 1.45)

44/39

0.88

(0.45, 1.70)

30/22

0.87

(0.39, 1.96)

High RPA

76/44

1.23

(0.72, 2.10)

46/23

1.55

(0.76, 3.16)

30/21

0.92

(0.41, 2.07)

CDH1

Inactive

55/39

1.00

reference

5/4

not estimated

50/35

1.00

reference

--

Low RPA

67/61

0.78

(0.45, 1.33)

4/7

not estimated

63/54

0.82

(0.47, 1.44)

High RPA

69/37

1.32

(0.75, 2.34)

2/1

not estimated

67/36

1.31

(0.72, 2.36)

CYCLIND2

Inactive

55/39

1.00

reference

12/13

1.00

reference

43/26

1.00

reference

0.115

Low RPA

67/61

0.78

(0.45, 1.33)

10/13

0.83

(0.26, 2.59)

57/48

0.72

(0.39, 1.34)

High RPA

69/37

1.32

(0.75, 2.34)

18/7

2.82

(0.87, 9.16)

51/30

1.03

(0.53, 2.00)

DAPK

Inactive

55/39

1.00

reference

11/6

1.00

reference

44/33

1.00

reference

0.145

Low RPA

67/61

0.78

(0.45, 1.33)

7/11

0.34

(0.09, 1.35)

60/50

0.90

(0.50, 1.62)

High RPA

69/37

1.32

(0.75, 2.34)

14/6

1.36

(0.33, 5.53)

55/31

1.33

(0.71, 2.51)

ESR1

Inactive

63/45

1.00

reference

30/21

1.00

reference

33/24

1.00

reference

0.194

Low RPA

73/60

0.87

(0.52, 1.45)

32/32

0.70

(0.33, 1.47)

41/28

1.06

(0.52, 2.18)

High RPA

76/44

1.24

(0.72, 2.11)

31/15

1.44

(0.63, 3.32)

45/29

1.13

(0.56, 2.29)

GSTP1

Inactive

55/39

1.00

reference

12/16

1.00

reference

43/23

1.00

reference

0.030

Low RPA

67/61

0.78

(0.45, 1.33)

16/10

2.33

(0.76, 7.17)

51/51

0.53

(0.28, 1.01)

High RPA

69/37

1.32

(0.75, 2.34)

18/11

2.33

(0.79, 6.84)

51/26

1.05

(0.53, 2.10)

HIN

Inactive

55/39

1.00

reference

33/18

1.00

reference

22/21

1.00

reference

0.207

Low RPA

67/61

0.78

(0.45, 1.33)

43/33

0.69

(0.33, 1.45)

24/28

0.82

(0.37, 1.84)

High RPA

69/37

1.32

(0.75, 2.34)

51/18

1.55

(0.70, 3.40)

18/19

0.92

(0.38, 2.21)

p16

Inactive

54/41

1.00

reference

2/2

not estimated

52/39

1.00

reference

--

Low RPA

66/61

0.82

(0.48, 1.40)

1/4

not estimated

65/57

0.85

(0.49, 1.47)

High RPA

70/39

1.36

(0.77, 2.39)

3/1

not estimated

67/38

1.32

(0.74, 2.35)

PR

Inactive

63/45

1.00

reference

5/8

not estimated

58/37

1.00

reference

--

Low RPA

74/61

0.87

(0.52, 1.45)

4/10

not estimated

70/51

0.88

(0.51, 1.52)

High RPA

76/44

1.23

(0.72, 2.10)

10/5

not estimated

66/39

1.08

(0.61, 1.91)

RARB

Inactive

55/39

1.00

reference

13/19

1.00

reference

42/20

1.00

reference

0.183

Low RPA

67/61

0.78

(0.45, 1.33)

16/19

1.23

(0.46, 3.24)

51/42

0.57

(0.29, 1.10)

High RPA

69/37

1.32

(0.75, 2.34)

16/12

1.96

(0.70, 5.49)

53/25

1.01

(0.49, 2.06)

RASSF1A

Inactive

55/39

1.00

reference

49/29

1.00

reference

6/10

1.00

reference

--

Low RPA

67/61

0.78

(0.45, 1.33)

57/51

0.66

(0.36, 1.19)

10/10

1.72

(0.44, 6.64)

High RPA

69/37

1.32

(0.75, 2.34)

57/32

1.06

(0.56, 1.98)

12/5

not estimated

TWIST

Inactive

55/39

1.00

reference

8/10

1.00

reference

47/29

1.00

reference

0.360

Low RPA

67/61

0.78

(0.45, 1.33)

9/12

0.86

(0.24, 3.15)

58/49

0.73

(0.40, 1.34)

 

High RPA

69/37

1.32

(0.75, 2.34)

 

11/6

2.39

(0.61, 9.46)

 

58/31

1.16

(0.61, 2.19)

 

a Low RPA ≤ 9.23 hours/week, High RPA > 9.23 hours/week

 

 

Table 4: Age-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the association between postmenopausal recreational physical activity (RPA) and ER+PR+ breast cancer (vs. all others: ER-PR-, ER+PR-, ER-PR+) considering gene-specific methylation status of the tumor (methylated vs. unmethylated), the Long Island Breast Cancer Study Project (1996-1997).